WHO mRNA Technology Transfer Programme — Afrigen's Cape Town Hub-and-Spoke Vaccine Network
South Africa
Since 2021, WHO and the Medicines Patent Pool have backed Afrigen Biologics in Cape Town to reverse-engineer and transfer mRNA …
Good practice
Imported
★ 81
★ 76
★ 76
★ 71
CIGB / BioCubaFarma — Cuba's State Biotechnology Technology-Transfer Engine
Cuba · Havana · See the Cuba profile · See the Havana profile
Evidence: Descriptive / self-reported Top 85% 52/100 · Ask Evidence Copilot about this practice
Cuba's CIGB, part of the BioCubaFarma group since 2012, holds 2,438 patents registered outside Cuba and sells in 50+ countries; during COVID-19 it transferred vaccine tech to Iran, Vietnam, Venezuela and Nicaragua, though figures are largely self-reported under a US embargo.
2,438
Patents registered outside Cuba
50+
Countries with registered/sold products
4
Countries with COVID-19 vaccine technology-transfer agreements
5
Additional countries approving CIGB-66 (Abdala) vaccine
40
Enterprises in BioCubaFarma group
Details
- Maturity
- Established
- Promoter
- Centro de Ingeniería Genética y Biotecnología (CIGB) / BioCubaFarma
- Period
- 1986-present
- Keywords
- biotechnology, vaccine R&D, patent portfolio, international technology-transfer agreements
Context
Cuba's Centro de Ingeniería Genética y Biotecnología (CIGB), founded in 1986, built a biotech R&D track record including a recombinant Hepatitis B vaccine, interferons and epidermal growth factor treatments, before being integrated in 2012 into BioCubaFarma, a state group of 40 biotech and pharmaceutical enterprises.
Objectives
The institution's aim, as part of BioCubaFarma, is to develop and export biotechnology and pharmaceutical products and to transfer vaccine and biotech production technology to allied countries.
Activities
During the COVID-19 pandemic CIGB developed the CIGB-66 (Abdala) vaccine and Cuba signed technology-transfer agreements to produce or supply its vaccines in Iran, Vietnam, Venezuela and Nicaragua.
Results
According to WIPO, BioCubaFarma holds 2,438 patents registered outside Cuba, with products registered and sold in more than 50 countries, and the Abdala vaccine was approved by Cuba's regulator and by regulators in five other countries.
Conclusions
CIGB/BioCubaFarma illustrates a sustained, state-led biotech technology-transfer model, though most reporting on its patent counts, export reach and transfer outcomes comes from Cuban state sources or international bodies relaying those figures rather than independently audited data.
Implementation
- Indicative cost
- High (€500k–€5M) — Multi-decade biotech R&D and manufacturing infrastructure across a 40-enterprise state group is consistent with a high overall cost base.
- Time to results
- Long (> 3 years) — Continuous operation from 1986 to the present, spanning nearly four decades.
- Staffing & skills
- CIGB research scientists and biotech engineers, BioCubaFarma group management coordinating 40 constituent enterprises, Government technology-transfer negotiators for bilateral agreements
Conditions for success
- State-directed, long-term R&D investment sustained across decades
- Integration into a larger industrial group (BioCubaFarma) enabling manufacturing and export scale
- Government-to-government relationships enabling technology-transfer agreements with allied states
Common failure modes
- Reliance on self-reported figures under a US embargo limits independent verification of patent, export and transfer claims
- Technology transfer concentrated in a small set of politically aligned recipient countries rather than an open multi-stakeholder model
Where it fits
- Governance type
- state-owned enterprise group
- Scale
- national institution with international export/transfer reach
- Income level
- embargoed, state-planned economy
Commonly funded by
National / regional programmes Own resources / municipal budget
Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.
Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.
Data sources
Where this practice's information was retrieved from, and when.
- C-NAPSE web research — accessed 2026-08-16
- Centro de Ingeniería Genética y Biotecnología (CIGB) / BioCubaFarma — accessed 2026-08-16
- Nature — BioCubaFarma: bringing Cuban biopharma to the world — accessed 2026-08-16
- WHO/IRIS — Cuban experience with local production of medicines, technology transfer — accessed 2026-08-16
- WIPO — Innovation and Technology Transfer in Cuba — accessed 2026-08-16
Attachments
Similar practices you may find useful
EMBRAPII — Brazil's Shared-Risk Industry–Research Innovation Financing Model
Brazil
Brazil's federal EMBRAPII co-funds R&D between research institutes and firms, splitting risk three ways. A first evaluation of 179 funded …
Saigon Hi-Tech Park — Ho Chi Minh City's Technology Transfer & Commercialisation Engine
Vietnam
Ho Chi Minh City's flagship tech park grew from 26 firms and $2bn invested (2011) to 160+ projects worth $13.7bn …
Hsinchu Science Park
Taiwan
Taiwan's flagship semiconductor science park, home to TSMC and UMC — 584 companies employing 177,000+ workers generated NT$1.51 trillion (~US$46bn) …